Healthcare and life sciences operate at the intersection of urgency and precision. A clinician performing cardiac ultrasound needs low-latency, real-time image formation and consistent frame rates to visualize a beating heart and guide decisions as physiology changes from beat to beat. Lab and diagnostic systems depend on controlled timing and traceable execution to support repeatability, quality control, and regulatory verification across high-throughput operation. A patient monitoring system must synthesize data from wearable sensors, bedside monitors, and imaging devices in real time, without sending sensitive patient information to a distant cloud.
These are not aspirational scenarios: they are the daily reality of clinical care, and they demand computing infrastructure that matches the stakes.
At Embedded World 2026, Intel expanded its edge AI portfolio with two processor families and a new software suite purpose-built for these challenges. Intel® Core™ Series 2 processors deliver the deterministic, real-time compute that medical devices and industrial healthcare systems require. Intel® Core™ Ultra Series 3 processors combine that same real-time precision with integrated AI acceleration for generative and agentic AI workloads, all in a single SoC. And the new Health and Life Sciences AI Suite provides an industry-optimized software stack that accelerates the path from prototype to production for multimodal patient monitoring, diagnostics, and clinical intelligence at the edge.
The Edge Is Where Clinical Decisions Happen
AI in healthcare is not new. Computer vision models have powered medical imaging analysis for years, and more than 1,000 AI/ML-enabled medical devices have been authorized by the FDA across specialties, reflecting rapid adoption in clinical workflows. What is new is the convergence of established techniques like machine learning and computer vision with the emerging capabilities of generative and agentic AI.
Agentic AI provides a framework that connects disparate technologies, enabling the collection of rich, contextual information vital for clinical solutions. Emerging ‘agentic’ approaches can help orchestrate clinical and operational workflows—for example, summarizing relevant context, surfacing supporting data, and assisting documentation—with clinicians retaining full decision authority. In addition to clinician-in-the-loop workflow design, agentic-based solutions are also subject to validation, intended-use labeling, and applicable regulatory review before clinical use.
The critical insight is that these workloads belong at the edge, not in the cloud.
When a clinician is imaging a patient’s beating heart, the processing must happen on or near the device with predictably low latency so results are available during the exam or bedside workflow. For many real-time and high-data-volume workflows, edge or on-prem processing is often the most practical architecture, reducing latency and supporting data locality requirements. Cloud connectivity can introduce latency, bandwidth, and governance complexity—so many time-sensitive workflows benefit from edge or on-prem execution, with cloud used where appropriate.
Deterministic Performance Is Not Optional in Healthcare
Consider cardiac diagnostics. ECG systems must maintain consistent sampling, signal fidelity, and lossless data handling so clinicians can rely on waveform morphology and alarms—especially under load and during continuous operation. In ultrasound imaging, a beating heart must be captured before the next contraction. In lab diagnostics, reproducibility depends on timing consistency across thousands of automated test cycles.
These are not edge cases: they are the core requirements of medical device computing.
Intel® Core™ Series 2 processors address these requirements with a uniform P-core architecture that delivers predictable, sub-millisecond response times. With up to 12 P-cores and up to 1.5x higher multi-threaded performance compared to the prior generation, this platform provides the raw compute headroom for data-intensive imaging, 3D reconstruction, and AI-assisted diagnostics. Intel® Time Coordinated Computing (TCC) and Time-Sensitive Networking (TSN) enable time-aware, deterministic execution, ensuring that critical cardiac signals, imaging frames, and diagnostic measurements are captured and analyzed exactly when they occur.
This deterministic advantage is measurable.
Compared to AMD’s 9700X at equivalent power, the Intel® Core™ Series 2 delivers up to 2.5x more deterministic scheduling behavior and up to 3.8x better predictable performance under load, as measured by industry-standard cyclictest and RTC Testbench benchmarks. Platform-level tuning delivers 4.4x lower maximum PCIe latency, keeping the data path from sensor to processor stable and awake. Real-time performance is about more than raw speed: it is about consistency, and consistency is what prevents dropped frames, missed waveform anomalies, and unreliable diagnostic results.
Each P-core delivers maximum throughput, reducing software costs associated with per-core licensing, a significant factor for healthcare OEMs deploying imaging software across large installed bases.
Integrated AI Acceleration Changes the Equation at the Edge
Intel® Core™ Series 2 delivers the deterministic foundation. Intel® Core™ Ultra Series 3 processors build on that foundation with integrated AI acceleration that brings generative and agentic AI workloads directly to the point of care, without requiring external accelerator cards.
Core Ultra Series 3 is our first processor to combine AI acceleration and real-time control in a single SoC. With up to 180 platform TOPS (1.8x generation over generation) distributed across CPU, GPU, and NPU, this processor runs multimodal AI pipelines concurrently: vision, language, sensor fusion, and time-series analysis, all within the same thermal envelope that edge medical devices demand. The hybrid CPU architecture pairs powerful cores for decision-making and critical compute tasks with increased GPU cores and an advanced integrated NPU for emerging AI workloads. Intel® TCC and discrete TSN remain fully supported, so real-time AI and simultaneous high-performance AI operations run together without compromise.
The performance benchmarks tell a compelling story. Against NVIDIA Jetson Orin AGX 64GB, Intel® Core™ Ultra Series 3 delivers up to 1.9x faster LLM performance on iGPU, up to 1.7x faster image classification, and up to 2.3x better performance per watt per dollar in video analytics. Real-world customer deployments show 39 to 67 percent TCO savings compared to alternative solutions that rely on discrete GPUs. Intel has demonstrated fine-tuning and inference running on the single SoC at 87 percent of discrete GPU performance, with 5.8x cost savings. One SoC that handles the most demanding AI workloads at the edge changes the deployment economics for healthcare organizations that need to scale AI from pilot to production across hundreds or thousands of devices.
For healthcare and life sciences specifically, this translates to sharper, more reliable imaging with AI-enhanced reconstruction, faster 3D rendering for radiology workstations, AI-assisted screening tools that combine computer vision with generative AI for richer diagnostic context, and ambient clinical intelligence systems that document and analyze patient encounters in real time.
The Health and Life Sciences AI Suite Accelerates Time to Value
Hardware capability alone does not solve the deployment challenge. Healthcare organizations need repeatable, scalable software paths that reduce integration complexity and shorten time to market. That is why Intel announced the preview of the Health and Life Sciences AI Suite at Embedded World 2026.
The Health and Life Sciences AI Suite features representative multimodal patient monitoring scenarios (e.g., simulated multi-parameter monitoring, ECG analytics, rPPG, and visual tracking) that run locally to help teams evaluate concurrency, latency, and availability at the edge. The new Health & Life Sciences AI Suite will be available later this quarter, but you can find information here.
The AI Suite is built on open-source foundations: the OpenVINO™ toolkit for AI optimization and inference across CPU, GPU, and NPU; Geti software for computer vision model development; DL Streamer for real-time video analytics pipelines; and the Edge Manageability Framework for zero-touch provisioning and remote asset management at scale. These are not proprietary lock-in tools. They are open, designed to protect R&D investment across hardware generations by ensuring model portability and performance optimization as platforms evolve. Check out the preview at GitHub.
Open Systems and a Proven Ecosystem Reduce Risk
Healthcare is a highly regulated industry where deployment risk, supply chain continuity, and total cost of ownership determine whether AI projects move from pilot to production. Intel’s approach is built to address these realities directly. More than 200 million x86 processors are deployed at the edge, with thousands of production AI systems running in healthcare, manufacturing, retail, and safety-critical environments. Over 4,000 integrators and ISVs form a global ecosystem that supports design, deployment, and lifecycle management.
Open software, open systems, and a proven ecosystem are not abstractions: they are the mechanisms that reduce risk for healthcare organizations. OpenVINO optimizes and scales AI across CPU, GPU, and NPU, maximizing performance and portability while protecting R&D investment across hardware generations. Intel® AI Edge Systems deliver pre-validated, benchmarked configurations that accelerate time to market. Intel vPro® provides resilient, autonomous remote management, eliminating the need to send field crews to repair frozen devices in clinical environments where downtime is not an option.
Intel’s perspective on AI integration underscores the importance of embedding AI within existing healthcare infrastructures, preventing the emergence of isolated systems.
Our approach ensures AI is a fully integrated component of a cohesive healthcare solution. By leveraging existing assets and interweaving AI into day-to-day clinical operations, organizations can maximize their technology investments to harness AI’s potential for better patient care without disrupting established workflows.
Real-World Impact: Customers Delivering Clinical Value with Intel
The promise of edge AI in healthcare is already being realized by organizations deploying Intel-powered solutions in production clinical environments:
- GE HealthCare partnered with Intel to embed AI directly into its Optima X-ray systems using the OpenVINO toolkit. The Critical Care Suite algorithms detect life-threatening conditions like pneumothorax within seconds, a 3.3x acceleration over unoptimized inference, enabling radiologists to prioritize critical cases immediately without disrupting existing clinical workflows.
- Advantech is showcasing AI-ready medical platforms powered by Intel processors that deliver real-time AI inference at the medical edge. These certified, purpose-built devices enable point-of-care intelligence across nurse stations, diagnostic imaging rooms, and mobile clinical carts, reducing latency and strengthening data security for healthcare organizations accelerating AI adoption.
- Onyx Healthcare, an Intel AI: In Production Partner, uses Intel-powered edge computing and the OpenVINO toolkit to deploy machine vision systems that identify medications with precision, reducing the risk of look-alike drug errors. The solution integrates seamlessly into pharmacy and nursing workflows, demonstrating how computer vision at the edge directly improves patient safety.
AI That Moves Healthcare Forward
The edge is entering a new wave of growth as agentic AI, computer vision, and generative models converge at the point of care. Intel’s portfolio is positioned for this moment.
These aren’t future promises. They’re production-ready capabilities backed by open software, proven silicon, and an ecosystem of thousands of partners.
Built with the ecosystem. Proven at the edge.
That’s the power of Intel Inside®.
_________________________________________________________
For notices, disclaimers, and details about certain performance claims, visit www.intel.com/PerformanceIndex